Nivolumab produces durable responses and long-term survival in severe liver cancer patients
Results from the CheckMate 040 study presented today found that nivolumab, an immuno-oncology drug which acts by modulating the immune system, produces durable responses with long-term survival rates, regardless of whether ...
Apr 21, 2017
0
1